All News Items
Berlin Summer Meeting: Sequencing Planet Earth
13.06.2025 / On June 19 and 20, the 2025 Berlin Institute of Systems Biology of the Max Delbrück Center Summer Meeting will explore how analyzing DNA and RNA can conserve biodiversity, ensure food security, and help detect and prevent disease. … more
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
06.06.2025 / Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor. … more
AI helps people and doctors make medical decisions
03.06.2025 / Online symptom checkers often miss the mark. Can AI do better? Researchers from Altuna Akalin’s team at MDC-BIMSB put large language models to the test – evaluating their ability to guide patients and support doctors. Their study was published in “npj Digital Medicine.” … more
Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
30.05.2025 / Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event gathered around 100 decision makers, renowned experts, key partners, and influential industry leaders to explore the transformative potential of radionuclides in precision oncology. … more
Knowledge for your ears
30.05.2025 / The Life Science Learning Lab has launched a new podcast intended to spark young people’s interest in research. During the first three episodes of “scienceCLASH,” students from Berlin interviewed Sarah Kedziora and Theda Bartolomaeus from the ECRC about the gut microbiome’s influence on heart health. … more
First vascularized model of stem cell islet cells
26.05.2025 / Researchers led by Maike Sander, Scientific Director of the Max Delbrück Center, have developed a vascularized organoid model of hormone secreting cells in the pancreas. The advance, published in “Developmental Cell,” promises to improve diabetes research and cell-based therapies. … more
Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
23.05.2025 / Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI), recognize excellently managed medium-sized companies throughout Germany. Eckert & Ziegler has now received this coveted award the second time. … more
Millions in funding for two Clusters of Excellence
23.05.2025 / The Max Delbrück Center is a partner in one newly awarded Berlin based Clusters of Excellence: ImmunoPreCept. NeuroCure has also won another round of funding. All researchers are working toward a common goal – to develop therapies that can intercept diseases on a molecular level. … more
Talk im Cube: International Cooperation and Funding programs in Life Sciences
15.05.2025 / We are excited to continue also in 2025 the Talks in the Cube starting with a further expert discussion focused on International cooperation and Funding programs in Life Sciences. … more
Towards understanding tumors in 3D
02.05.2025 / Researchers in Nikolaus Rajewsky’s lab at Max Delbrück Center combined high-resolution, single-cell spatial technologies to map a tumor’s cellular neighborhoods in 3D and identify potential targets for personalized cancer therapy. They describe their findings in two separate papers in “Cell Systems.” … more
Helmholtz Drug Discovery Conference kommt nach Berlin
24.04.2025 / Vom 28. bis 30. April treffen sich führende Wirkstoffforscher*innen und Unternehmen am Max Delbrück Center. Auf der Helmholtz Drug Discovery Conference 2025 werden sie über RNA-basierte Therapien, PROTACs, KI für die Medikamentenentwicklung und Chemoproteomik diskutieren und neue Kooperationen schmieden. … more
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
24.04.2025 / Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. … more
How the heart and blood vessels influence organs
24.04.2025 / The Helmholtz Institute for Translational AngioCardioScience (HI-TAC) invites attendees to its first Symposium on April 28 and 29, 2025. Researchers from around the world will meet at Heidelberg University to discuss how the heart and blood vessels communicate with the rest of the body to shape health. … more
Consortium of African and European research institutions secures €1.5 million grant to build capacity for early drug discovery in sub-Saharan Africa
23.04.2025 / An African and European research consortium receives €1.5 million from the European Union and additional resources from the Swiss government to support the accumulation of knowledge, skills and innovative capacities for drug discovery in sub-Saharan Africa. The associated project “RAFIKI”, which launched in January 2025, will tackle pressing public health challenges and build new avenues for cooperation between African and European researchers. … more
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
25.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further develop its promising lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. … more
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
20.03.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing. … more
Inflammatory messenger fuels Alzheimer’s
18.03.2025 / Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer’s disease. The study was published in the journal “Nature Aging.” … more
New treatment approach for rare blood cancer of the skin
10.03.2025 / Researchers from Medical University of Vienna, Charité Berlin and Max Delbrück Center have identified the CD74 protein as a new drug target to treat deadly skin lymphoma. The study was published in the “British Journal of Dermatology.” … more
Inequality raises disease risk, especially for women
07.03.2025 / A study led by researchers at the Max Delbrück Center has found that low socioeconomic status raises the risk of cardiovascular disease in women more so than in men. The study underlines the importance of gender-specific prevention. … more
“Jugend forscht” at Campus Berlin-Buch
03.03.2025 / From better 3D printers for biological structures to soil remediation with microorganisms – in the 60th round of “Jugend forscht,” regional students presented their exciting research projects on the Berlin-Buch campus. … more
Not all heart inflammation is the same
25.02.2025 / A group of Berlin researchers in collaboration with international scientists have found differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccination, and non-COVID-19 myocarditis. The find paves the way for more personalized therapies, they report in “Nature Cardiovascular Research.” … more
Access to high-performance computing for businesses
20.02.2025 / Helmholtz invests €18 million in AI innovation ecosystems: Nine Helmholtz centers open their High-Performance Computing infrastructure to companies and connect businesses with their AI experts. More than €2 million will go to the Max Delbrück Center. … more
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
07.02.2025 / Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC). … more
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
31.01.2025 / Tubulis (a joint spin-off of the FMP and the Ludwig-Maximilians-Universität Munich) announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The study is evaluating TUB-030, Tubulis’ next-generationntibodydrug conjugate (ADC), in patients with advanced solid tumors. The ADC targets 5T4, an oncofetal antigen expressed in a broad range of solid tumors. The program was developed using Tubulis’ proprietary Tubutecan linker-payload platform, which enables superior biophysical properties for precise and sustained on-tumor payload delivery. … more
Heike Graßmann new State Secretary in Saxony
17.01.2025 / The Max Delbrück Center congratulates Professor Heike Graßmann, who has served as Administrative Director of the research center since 2018, on her appointment as State Secretary for Science, Culture, and Tourism in Saxony. Graßmann will assume her new role in Dresden on February 1, 2025. … more
FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
15.01.2025 / Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). … more
Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
15.01.2025 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. … more
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
13.01.2025 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global supply agreement for Actinium-225 (Ac-225). Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical research and development activities on innovative alpha radiotherapeutics. … more
Developing a CRISPR therapy for muscular dystrophy
07.01.2025 / Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in “Nature Communications” now paves the way for first-in-human clinical trials. … more
Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
13.12.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan. … more
Leibniz Prize awarded to Ana Pombo
11.12.2024 / The German Research Foundation (DFG) has announced that biochemist Ana Pombo from the Max Delbrück Center is among this year’s winners of the Gottfried Wilhelm Leibniz Prize. With a grant of €2.5 million, the Leibniz Prize is one of the highest endowed research prizes in Germany. … more
Inspiring and connecting: “Talk im Cube”
09.12.2024 / For almost a year, “Talk im Cube” has been bringing science and business together on the Campus Berlin-Buch … more
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
06.12.2024 / Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global supply agreement for the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). … more
Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
03.12.2024 / The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. … more
The Max Delbrück Center bids farewell to Thomas Sommer
03.12.2024 / For three decades, Thomas Sommer conducted research at the Max Delbrück Center and shaped its development: as a scientist, ombudsman, committee representative, and interim board member. On December 6, the center will honor him with a symposium on his favorite topic — the cell's recycling system. … more
Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
02.12.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product. … more
Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
28.11.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand® in routine clinical applications throughout the European Economic Area (EEA). … more
Berlin goes USA
21.11.2024 / Strengthening transatlantic economic relations: Berlin delegation trip to the USA - with a focus on life science and health … more
Max Delbrück Center signs licence agreement with Kite, a Gilead Company, for Sleeping Beauty Transposon System
20.11.2024 / Supported by its technology transfer partner Ascenion, Max Delbrück Center has entered into a licensing agreement with Kite providing the company with non-exclusive rights to use the transposon system for the genetic engineering of T cells. … more
Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
14.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 million or € 1.12 per share. … more
Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
13.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix totaling up to € 20 million within approximately two years, as well as access to a higher availability of Ac-225. … more
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
08.10.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its GMP grade non-carrier added Lutetium-177 chloride (n.c.a. Lu-177) for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers. … more
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
02.10.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG. … more
OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
27.09.2024 / Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025 … more
